Revenue (Tables)

6 Months Ended

Jun. 30, 2026

Revenue from Contract with Customer [Abstract]

Schedule of Revenue by Sales Category

The following tables provide detail by sales category:


						Three Months Ended June 30, 2026																		Three Months Ended June 30, 2025
(in millions)						U.S.						Int’l						Total						U.S.						Int’l						Total
Established Pharmaceutical Products —
Key Emerging Markets						$	—					$	1,164					$	1,164					$	—					$	1,059					$	1,059
Other						—						335						335						—						324						324
Total						—						1,499						1,499						—						1,383						1,383
Nutritional Products —
Pediatric Nutritionals						525						500						1,025						587						467						1,054
Adult Nutritionals						346						773						1,119						370						788						1,158
Total						871						1,273						2,144						957						1,255						2,212
Diagnostic Products —
Core Laboratory						377						1,041						1,418						351						1,007						1,358
Rapid and Molecular						393						362						755						460						355						815
Cancer Diagnostics						890						29						919						—						—						—
Total						1,660						1,432						3,092						811						1,362						2,173
Medical Devices —
Rhythm Management						377						366						743						340						333						673
Electrophysiology						420						441						861						362						393						755
Heart Failure						313						88						401						282						86						368
Vascular						294						509						803						283						474						757
Structural Heart						225						372						597						249						332						581
Neuromodulation						189						71						260						193						61						254
Diabetes Care						862						1,326						2,188						794						1,187						1,981
Total						2,680						3,173						5,853						2,503						2,866						5,369

Other						5						—						5						5						—						5

Total						$	5,216					$	7,377					$	12,593					$	4,276					$	6,866					$	11,142


						Six Months Ended June 30, 2026																		Six Months Ended June 30, 2025
(in millions)						U.S.						Int’l						Total						U.S.						Int’l						Total
Established Pharmaceutical Products —
Key Emerging Markets						$	—					$	2,253					$	2,253					$	—					$	2,024					$	2,024
Other						—						672						672						—						619						619
Total						—						2,925						2,925						—						2,643						2,643
Nutritional Products —
Pediatric Nutritionals						1,036						942						1,978						1,175						920						2,095
Adult Nutritionals						679						1,504						2,183						737						1,526						2,263
Total						1,715						2,446						4,161						1,912						2,446						4,358
Diagnostic Products —
Core Laboratory						724						1,966						2,690						683						1,852						2,535
Rapid and Molecular						858						709						1,567						999						693						1,692
Cancer Diagnostics						983						32						1,015						—						—						—
Total						2,565						2,707						5,272						1,682						2,545						4,227
Medical Devices —
Rhythm Management						716						711						1,427						644						614						1,258
Electrophysiology						798						851						1,649						695						735						1,430
Heart Failure						605						185						790						544						163						707
Vascular						585						995						1,580						551						916						1,467
Structural Heart						449						726						1,175						497						615						1,112
Neuromodulation						366						137						503						369						113						482
Diabetes Care						1,684						2,584						4,268						1,542						2,266						3,808
Total						5,203						6,189						11,392						4,842						5,422						10,264

Other						7						—						7						8						—						8

Total						$	9,490					$	14,267					$	23,757					$	8,444					$	13,056					$	21,500

___________________________________


Notes:			Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the second quarter of 2025 and $101 million of sales in the first six months of 2025 were moved from Structural Heart to Electrophysiology.
			Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business.
			On March 23, 2026, Abbott completed the acquisition of Exact Sciences Corporation (Exact Sciences). Following the acquisition, the sales of Exact Sciences are presented as Cancer Diagnostics.

Schedule of Changes in Contract Liabilities

Changes in the contract liabilities during the period are as follows:


(in millions)
Contract Liabilities:
Balance at December 31, 2025						$	633
Unearned revenue from cash received during the period						271
Revenue recognized related to contract liability balance						(244)
Balance at June 30, 2026						$	660